Literature DB >> 23640129

Chromophobe hepatocellular carcinoma with abrupt anaplasia: a proposal for a new subtype of hepatocellular carcinoma with unique morphological and molecular features.

Laura D Wood1, Christopher M Heaphy, Hubert Darius-J Daniel, Bita V Naini, Charles R Lassman, May R Arroyo, Ihab R Kamel, David P Cosgrove, John K Boitnott, Alan K Meeker, Michael S Torbenson.   

Abstract

Hepatocellular carcinomas exhibit heterogeneous morphologies by routine light microscopy. Although some morphologies represent insignificant variations in growth patterns, others may represent unrecognized subtypes of hepatocellular carcinoma. Identification of these subtypes could lead to separation of hepatocellular carcinomas into discrete groups with unique underlying genetic changes, prognosis, or therapeutic responses. In order to identify potential subtypes, two pathologists independently screened a cohort of 219 unselected hepatocellular carcinoma resection specimens and divided cases into potential subtypes. One of these promising candidate subtypes was further evaluated using histological and molecular techniques. This subtype was characterized by a unique and consistent set of histological features: smooth chromophobic cytoplasm, abrupt focal nuclear anaplasia (small clusters of tumor cells with marked nuclear anaplasia in a background of tumor cells with bland nuclear cytology), and scattered microscopic pseudocysts--we designate this variant as 'chromophobe hepatocellular carcinoma with abrupt anaplasia'. Thirteen cases were identified (6% of all hepatocellular carcinomas), including 6 men and 7 women with an average age of 61 years. Six cases occurred in cirrhotic livers. Serum AFP was elevated in 6 out of 10 cases. There were a variety of underlying liver diseases, but cases were enrichment for chronic hepatitis B, P=0.006. Interestingly, at the molecular level, this variant was strongly associated with the alternative lengthening of telomere (ALT) phenotype by telomere FISH. ALT is a telomerase-independent mechanism of telomere maintenance and is found in approximately 8% of unselected hepatocellular carcinomas. In contrast, 11/12 (92%) of the cases of chromophobe hepatocellular carcinoma with abrupt anaplasia were ALT-positive. In summary, we propose that chromophobe hepatocellular carcinoma with abrupt anaplasia represents a new subtype of hepatocellular carcinoma with unique morphological and molecular features.

Entities:  

Mesh:

Year:  2013        PMID: 23640129      PMCID: PMC3974906          DOI: 10.1038/modpathol.2013.68

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  15 in total

1.  The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies.

Authors:  Yutong Xue; Richard Gibbons; Zhijiang Yan; Dafeng Yang; Tarra L McDowell; Salvatore Sechi; Jun Qin; Sharleen Zhou; Doug Higgs; Weidong Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-02       Impact factor: 11.205

2.  Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres.

Authors:  Peter W Lewis; Simon J Elsaesser; Kyung-Min Noh; Sonja C Stadler; C David Allis
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-22       Impact factor: 11.205

Review 3.  Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice.

Authors:  Masatoshi Kudo
Journal:  Int J Clin Oncol       Date:  2010-05-28       Impact factor: 3.402

4.  Fighting the bushfire in HCC trials.

Authors:  Peter Schirmacher; Pierre Bedossa; Tania Roskams; Dina G Tiniakos; Elizabeth M Brunt; Jessica Zucman-Rossi; Michael P Manns; Peter R Galle
Journal:  J Hepatol       Date:  2011-03-22       Impact factor: 25.083

Review 5.  Alternative lengthening of telomeres: models, mechanisms and implications.

Authors:  Anthony J Cesare; Roger R Reddel
Journal:  Nat Rev Genet       Date:  2010-03-30       Impact factor: 53.242

Review 6.  Assaying and investigating Alternative Lengthening of Telomeres activity in human cells and cancers.

Authors:  Jeremy D Henson; Roger R Reddel
Journal:  FEBS Lett       Date:  2010-06-11       Impact factor: 4.124

Review 7.  The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective.

Authors:  Alan P Venook; Christos Papandreou; Junji Furuse; Laura Ladrón de Guevara
Journal:  Oncologist       Date:  2010

8.  Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma.

Authors:  Wing-Kin Sung; Hancheng Zheng; Shuyu Li; Ronghua Chen; Xiao Liu; Yingrui Li; Nikki P Lee; Wah H Lee; Pramila N Ariyaratne; Chandana Tennakoon; Fabianus H Mulawadi; Kwong F Wong; Angela M Liu; Ronnie T Poon; Sheung Tat Fan; Kwong L Chan; Zhuolin Gong; Yujie Hu; Zhao Lin; Guan Wang; Qinghui Zhang; Thomas D Barber; Wen-Chi Chou; Amit Aggarwal; Ke Hao; Wei Zhou; Chunsheng Zhang; James Hardwick; Carolyn Buser; Jiangchun Xu; Zhengyan Kan; Hongyue Dai; Mao Mao; Christoph Reinhard; Jun Wang; John M Luk
Journal:  Nat Genet       Date:  2012-05-27       Impact factor: 38.330

Review 9.  Review of the clinicopathologic features of fibrolamellar carcinoma.

Authors:  Michael Torbenson
Journal:  Adv Anat Pathol       Date:  2007-05       Impact factor: 3.875

10.  Fibrolamellar carcinomas are positive for CD68.

Authors:  Hillary M Ross; Hubert D J Daniel; Perumal Vivekanandan; Rajesh Kannangai; Matthew M Yeh; Tsung-Teh Wu; Hala R Makhlouf; Michael Torbenson
Journal:  Mod Pathol       Date:  2010-11-26       Impact factor: 7.842

View more
  13 in total

Review 1.  Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy.

Authors:  Renumathy Dhanasekaran; Jean-Charles Nault; Lewis R Roberts; Jessica Zucman-Rossi
Journal:  Gastroenterology       Date:  2018-11-04       Impact factor: 22.682

Review 2.  Emerging Role of the Pathologist in Precision Medicine for HCC.

Authors:  Thomas Longerich; Peter Schirmacher
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

Review 3.  Extra-telomeric impact of telomeres: Emerging molecular connections in pluripotency or stemness.

Authors:  Soujanya Vinayagamurthy; Akansha Ganguly; Shantanu Chowdhury
Journal:  J Biol Chem       Date:  2020-05-22       Impact factor: 5.157

4.  DNAJB1-PRKACA is specific for fibrolamellar carcinoma.

Authors:  Rondell P Graham; Long Jin; Darlene L Knutson; Sara M Kloft-Nelson; Patricia T Greipp; Nina Waldburger; Stephanie Roessler; Thomas Longerich; Lewis R Roberts; Andre M Oliveira; Kevin C Halling; Peter Schirmacher; Michael S Torbenson
Journal:  Mod Pathol       Date:  2015-02-20       Impact factor: 7.842

5.  Clinicopathological indices to predict hepatocellular carcinoma molecular classification.

Authors:  Poh Seng Tan; Shigeki Nakagawa; Nicolas Goossens; Anu Venkatesh; Tiangui Huang; Stephen C Ward; Xiaochen Sun; Won-Min Song; Anna Koh; Claudia Canasto-Chibuque; Manjeet Deshmukh; Venugopalan Nair; Milind Mahajan; Bin Zhang; Maria Isabel Fiel; Masahiro Kobayashi; Hiromitsu Kumada; Yujin Hoshida
Journal:  Liver Int       Date:  2015-06-29       Impact factor: 5.828

Review 6.  The role of telomeres and telomerase in cirrhosis and liver cancer.

Authors:  Jean-Charles Nault; Massih Ningarhari; Sandra Rebouissou; Jessica Zucman-Rossi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-06-28       Impact factor: 46.802

Review 7.  Hepatocellular carcinoma: making sense of morphological heterogeneity, growth patterns, and subtypes.

Authors:  Michael S Torbenson
Journal:  Hum Pathol       Date:  2020-12-30       Impact factor: 3.526

Review 8.  Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances.

Authors:  Renumathy Dhanasekaran; Salome Bandoh; Lewis R Roberts
Journal:  F1000Res       Date:  2016-05-12

Review 9.  The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) Phenotype.

Authors:  João P Amorim; Gustavo Santos; João Vinagre; Paula Soares
Journal:  Genes (Basel)       Date:  2016-09-19       Impact factor: 4.096

10.  Molecular testing for the clinical diagnosis of fibrolamellar carcinoma.

Authors:  Rondell P Graham; Matthew M Yeh; Dora Lam-Himlin; Lewis R Roberts; Luigi Terracciano; Michael W Cruise; Patricia T Greipp; Riyam T Zreik; Dhanpat Jain; Nida Zaid; Safia N Salaria; Long Jin; Xiaoke Wang; Jeanette G Rustin; Sarah E Kerr; William R Sukov; David A Solomon; Sanjay Kakar; Emily Waterhouse; Ryan M Gill; Linda Ferrell; Venancio Af Alves; Deniz Nart; Funda Yilmaz; Stephanie Roessler; Thomas Longerich; Peter Schirmacher; Michael S Torbenson
Journal:  Mod Pathol       Date:  2017-09-01       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.